Cancer and Chronic Inflammation: How Systemic Inflammation Drives Tumour Risk Years Before Diagnosis

Most people think of cancer as something that either happens to them or doesn't. Biology tells a different story. Chronic inflammation, which is the persistent, low-grade immune activation that accumulates silently over years, is one of the most well-documented biological drivers of cancer risk. Unlike acute inflammation, which resolves once a threat is cleared, chronic inflammation creates a sustained hostile tissue environment that can promote cellular damage, impair immune surveillance, and set the conditions for malignant transformation years before any diagnosis.

Understanding this connection matters because it shifts cancer prevention from a reactive to a proactive discipline. For a deeper grounding in how chronic inflammation drives biological aging across all disease categories, see our guide Chronic Inflammation & Inflammaging: The Hidden Driver of How You Age.

How does chronic inflammation actually create conditions for cancer to develop?

Chronic inflammation promotes cancer risk through a cycle of tissue damage, impaired repair, and immune dysregulation that compounds over time. Sometimes the inflammatory response fails to resolve, either because an acute trigger was never cleared or because lifestyle factors keep the immune system constantly activated. When that happens, pro-inflammatory molecules continue to circulate, damaging healthy tissue. This damage generates damage-associated molecular patterns (DAMPs), such as cellular debris, excess glucose, and cholesterol crystals, that perpetuate the inflammatory signal. This persistent low-grade activation consumes energy, leaves microscopic scars of damage that are repeatedly repaired, and creates a microenvironment in which abnormal cells are less effectively identified and eliminated.

"Low-grade chronic inflammation happening all around the body all the time is consuming a huge amount of energy and at the same time leaving microscopic scars of damage which are being repaired, which then promotes more inflammation — it is actually a vicious circle which leads to aging."

— Prof. Gordan Lauc, Co-Founder & Chief Scientific Officer, GlycanAge

That same vicious circle is the tissue context in which cancer risk accumulates. Researchers have a name for this state of chronic, low-grade immune activation: inflammaging.

What is inflammaging, and why does it matter for cancer prevention?

Inflammaging is the gradual, age-related increase in systemic chronic inflammation that occurs even in the absence of infection or injury. The term captures the observation that aging itself is both a cause and a consequence of chronic immune activation: as we age, inflammatory signaling increases; that inflammation, in turn, accelerates biological aging and raises the risk of age-related diseases, including cancer. Two proposed mechanisms drive inflammaging: mitochondrial dysfunction and a decline in autophagy. Mitochondrial dysfunction is a decline in the efficiency of the cell's energy-producing machinery, which can lead to increased oxidative stress, whereas autophagy is the cellular process that clears damaged components.

A decline in autophagy is officially one of the twelve hallmarks of aging, alongside chronic inflammation and mitochondrial dysfunction. The hallmarks are interrelated, with each one associated with and amplified by the others. For cancer prevention, inflammaging matters because it means the inflammatory environment that enables tumour development is not a sudden event but a slow accumulation. It begins decades before diagnosis and is, in principle, measurable and modifiable.

Why don't standard blood tests catch chronic inflammation early enough to be useful for cancer prevention?

Standard inflammatory markers, including TNF-alpha, ESR, and high-sensitivity CRP, are primarily measures of acute inflammation, not the chronic, low-grade immune activation that precedes disease. These markers tend to change close to the point at which disease has already taken hold, which means they are most informative when it is already late to intervene. What preventive medicine requires is a marker that changes well before disease appears. It should be one that captures the slow inflammatory trajectory rather than the acute spike.

As one GlycanAge's Chief Science Officer, the world's leading specialist in glycobiology, summarized in a clinical webinar:

"In many inflammatory diseases, IgG glycans change up to a decade before people get diagnosed with a disease. These molecular changes are something that happens very early, and with time becomes a disease. Glycans can be intermediate endpoints — early markers you can measure to predict whether there will be improvement in disease prevention or even mortality prevention."

— Prof. Gordan Lauc, Co-Founder & Chief Scientific Officer, GlycanAge

Generic blood panels also fluctuate on hourly and daily timescales, making them poorly suited to tracking the kind of slow biological drift that characterizes inflammaging and cancer-relevant immune aging.

Glycans: an early alternative to traditional markers and blood panels

Glycans are complex sugar molecules that coat the surface of virtually every cell in the human body and regulate how cells communicate, how the immune system responds, and whether antibodies promote or suppress inflammation. Approximately 60% of all human proteins are glycosylated, meaning glycans are attached to them through a tightly regulated enzymatic process, and this glycosylation determines whether a protein functions in a pro- or anti-inflammatory direction.

In the context of cancer, glycans are directly relevant: cancer cells are known to use altered glycan structures to evade immune detection, and the immune system itself communicates largely through glycan-mediated signaling. Chronic inflammation disrupts the glycosylation machinery, which are the enzymes responsible for attaching glycans to proteins. This produces aberrantly glycosylated antibodies, which shift the immune system toward a more pro-inflammatory state. As a result, the immune system becomes less able to identify and eliminate abnormal cells. Glycan changes associated with specific diseases, including cardiovascular disease, type 2 diabetes, rheumatoid arthritis, and Crohn's disease, have been detected up to ten years before clinical diagnosis, underlining the predictive window that glycan biology provides for disease prevention.

How does GlycanAge measure chronic inflammation, and what does it reveal about cancer-relevant immune aging?

GlycanAge measures the glycans attached to Immunoglobulin G (IgG) antibodies, which are the primary antibodies of the adaptive immune system, from a simple finger-prick blood sample. By analyzing the ratio of pro-inflammatory to anti-inflammatory IgG glycan structures, GlycanAge calculates a biological age that reflects how fast the immune system is aging, as distinct from chronological age. This matters for cancer risk because the shift from immunosuppressive glycans (which dampen inflammation) to pro-inflammatory glycans (which amplify it) is not merely a biomarker of immune aging. It is a functional change in the molecules that regulate whether the immune system can mount an effective surveillance response.

"Glycans are not only biomarkers — they are actually functional effectors which decide whether a specific antibody will promote inflammation or will it suppress inflammation."

— Prof. Gordan Lauc, Co-Founder & Chief Scientific Officer, GlycanAge

Measuring this shift gives a direct window into the inflammatory biology that precedes disease, including the immune dysregulation associated with cancer risk.

Why is early detection of chronic inflammation so important if cancer takes years to develop?

The argument for early detection of chronic inflammation rests on the same logic that Dr. Azra Raza, oncologist and author, has articulated in the context of cancer prevention: by the time cancer declares itself clinically, there are already hundreds of millions of cells involved, and the biology has been building for years. Dr. Raza has argued that the future of cancer research and treatment lies in going after the first cell, in prevention and early detection rather than late-stage intervention, and that this requires studying people at risk before symptoms emerge.

Chronic inflammation is precisely the kind of pre-disease signal that makes this possible. Elevated inflammatory markers predict higher mortality risk, and inflammaging is a leading contributor to three out of five deaths worldwide. Measuring and addressing chronic inflammation years before disease appears is the biological equivalent of going after the first cell, intervening in the environment that enables cancer to develop, rather than waiting for it to declare itself.

Can lifestyle changes reduce cancer-linked inflammation?

Chronic inflammation is driven by modifiable lifestyle factors, such as poor diet, physical inactivity, smoking, high adiposity, disturbed sleep, psychological stress, and social isolation, as well as by age-related biological changes including microbiome dysbiosis and mitochondrial dysfunction. This means the inflammatory environment associated with cancer risk is not fixed; it responds to targeted intervention.

The challenge has always been measurement: without a reliable biomarker that captures chronic inflammation specifically and responds to change, it is impossible to know whether an intervention is working at the biological level that matters. GlycanAge addresses this directly. IgG glycan profiles respond to dietary change, weight loss, exercise, supplementation, and hormone optimization, and meaningful changes are detectable within three to six months of a targeted intervention. This response window is fast enough to be actionable and stable enough to filter out the daily fluctuations that make standard blood markers unreliable for tracking slow biological change. The average biological age reduction across repeat GlycanAge testers is six years. This shows a measurable shift in the immune aging trajectory that standard panels cannot capture.

How is GlycanAge different from epigenetic clocks when it comes to tracking inflammation-related cancer risk?

Epigenetic clocks measure DNA methylation patterns, which are the changes in gene expression that accumulate over time, and provide a historical view of biological aging. They do not measure active, current inflammation directly, and their repeat-measurement variability is substantial: readings in the same individual can vary by up to ten years in the absence of any intervention or health event, making it difficult to distinguish a real biological change from analytical noise. GlycanAge, by contrast, measures the active inflammatory biology driving immune aging right now, with repeat measurements varying by approximately one year.

For tracking the chronic inflammatory environment relevant to cancer risk, and for knowing whether a lifestyle or medical intervention is actually shifting that environment, this reproducibility advantage is decisive. Epigenetic clocks tell you where you have been; GlycanAge tells you where you are, and whether you are moving in the right direction.

Next steps for measuring chronic inflammation and cancer-related immune aging

The first step is to establish a baseline biological age through IgG glycan analysis, which is a measurement that captures the current state of immune aging and chronic inflammation, not a static genetic readout or a fluctuating acute-phase marker. From that baseline, targeted lifestyle interventions, such as addressing diet, physical activity, sleep, stress, and where clinically appropriate, hormonal or pharmacological support, can be introduced and tracked through repeat testing at three-to-six-month intervals.

For individuals already working with a functional medicine practitioner or longevity clinician, GlycanAge results can be interpreted alongside clinical history, standard blood work, and other biomarkers to build a complete picture of inflammatory risk. The goal is not to diagnose cancer or predict it with certainty, since GlycanAge is a biomarker of immune aging and chronic inflammation, not a diagnostic tool, but to identify and address the biological conditions that make disease more likely, years before symptoms appear.

Integrate GlycanAge into your practice → For Healthcare Providers

If you want to know where your immune system stands today, and whether your current lifestyle is moving your inflammatory biology in the right direction, a GlycanAge test gives you a direct, science-backed answer. Every test includes a 1:1 Result Interpretation Call with a longevity specialist who will walk you through your biological age, your glycan profile, and a personalized plan for reducing chronic inflammation.

Order your GlycanAge test kit — and measure the biology that matters.

External Sources

• https://www.nature.com/articles/s41591-019-0675-0 — Furman D, Campisi J, Verdin E, et al. "Chronic inflammation in the etiology of disease across the life span." Nature Medicine. 2019;25(12):1822–1832.

• https://pubmed.ncbi.nlm.nih.gov/30107893/ — Gudelj I, Lauc G, Pezer M. "Immunoglobulin G glycosylation in aging and diseases." Cellular Immunology. 2018;333:65–79.

• https://www.scientificamerican.com/article/we-must-find-ways-to-detect-cancer-much-earlier/ — Raza A, et al. (The Oncology Think Tank). "We Must Find Ways to Detect Cancer Much Earlier." Scientific American. January 8, 2021.

• https://www.cell.com/cell/comments/S0092-8674(10)00060-7 — Grivennikov SI, Greten FR, Karin M. "Immunity, Inflammation, and Cancer." Cell. 2010;140(6):883–899.

• https://www.nature.com/articles/s41580-023-00585-7 — Gems D, de Magalhães JP. "Hallmarks of aging: An expanding universe." Nature Reviews Molecular Cell Biology. 2024;25(2):96–118.